<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The antithrombotic activity of a 2-kDa <z:chebi fb="5" ids="28304">heparin</z:chebi> fragment was studied in a rat model of common carotid artery <z:mp ids='MP_0005048'>thrombosis</z:mp> that causes a completely occlusive <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> with cessation of the blood flow within 10-15 min </plain></SENT>
<SENT sid="1" pm="."><plain>The compound reduced <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> formation in a dose-dependent manner, starting from an intravenous dose of 5 mg kg-1 </plain></SENT>
<SENT sid="2" pm="."><plain>A dose of 20 mg kg-1 completely prevented <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> formation and apparently induced the almost complete lysis of the already formed occlusive <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>At none of the doses used did the compound cause increased <z:mp ids='MP_0001914'>bleeding</z:mp> or the formation of haematomas </plain></SENT>
<SENT sid="4" pm="."><plain>The present results indicate that low molecular weight <z:chebi fb="0" ids="24505">heparins</z:chebi>, which have an established, highly beneficial effect in venous <z:hpo ids='HP_0001907'>thromboembolism</z:hpo>, are also highly effective in an animal model of <z:hpo ids='HP_0004420'>arterial thrombosis</z:hpo> </plain></SENT>
</text></document>